Unfortunately FDA-approved chemotherapy and immunotherapy used against advanced metastatic melanoma such as dacarbazine (DTIC), interferon (IFN) and interleukin-2 (IL-2) do not significantly improve patient outcomes in the majority (>80%) of patients [5]. This evidence concerns the gene IL2 and metastatic melanoma.